Theratech
ShareCopied to clipboardTheratech is a company. It is a public company in Montreal, Canada. It was founded in 1993 and its current CEO is Paul Lévesque. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Montreal
- country: Canada
- revenues: 85.9M $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 1993
- CEO: Paul Lévesque
- ESG score: 75.57 / 100
See more facts
Extract data
Download datasets about Theratech :
Dataset of stocks from Theratech :
Theratech is one of the companies in Canada, companies in Biotechnology, companies in Health Care, companies in Montreal and 3,456,808 companies in our database.
Talking Points
- Specialized Therapies | HIV and Oncology | Theratechnologies Inc.
- The Investor Relations website contains information about Theratechnologies Inc.'s business for stockholders, potential investors, and financial analysts.
- Health innovation that matters | Des innovations en santé qui font une différence #HIV #NASH #Oncology
- Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company. | Theratechnologies is a commercial-stage biopharmaceutical company. We currently market prescription products in the United States, Europe and Canada. Our commercialized products and our research pipeline focus on specialized therapies addressing ...
- Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.